Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacotherapy relapse prevention in body dysmorphic disorder.

Trial Profile

Pharmacotherapy relapse prevention in body dysmorphic disorder.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Somatoform disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 Apr 2016 Primary endpoint of relapse of body dysmorphic disorder (BDD) symptoms (as Measured by the BDD-YBOCS) has been met, according to results published in the American Journal of Psychiatry.
    • 08 Apr 2016 Results published in the American Journal of Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top